89bio
BiotechUnited States
1
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
8
Indications↗
Distinct diseases across all programs
10
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
1 drugs in development
Phase 31
Phase 21
By Therapeutic Area
top 2
Gastroenterology
133%
Metabolic & Endocrine
133%
R&D Momentum
23/100
Pipeline Velocity
0/100
Trial Completion Rate
100/100
Pipeline Concentration
33/100
Pipeline Freshness
78/100
Strategic Signals
- ↗Active in Gastroenterology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Jul 14, 2026
Recruiting
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ENLIGHTEN-Cirrhosis)
Jul 14, 2026
Recruiting
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Jul 8, 2026
Completed
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia (SHTG): The ENTRUST Study
Earlier
Mar 18, 2026TrialENLIVEN: Pegozafermin in NASH/MASH
Aug 16, 2021TrialPK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis
Sep 1, 2020TrialStudy to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia
Jul 29, 2019TrialA Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Metabolic & Endocrine
Unknown / Other
Gastroenterology
Metabolic & Endocrine
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
PegozaferminPhase 3
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
PegozaferminPhase 3
NASH/MASH
PegozaferminPhase 3
Unknown / Other
Fibrosis
PegozaferminPhase 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)